Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.70 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.70 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.70 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.70 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.70 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2685292 | 0.92 | HDAC1 (0.70) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL14775972 | 0.91 | KCNH2 (0.63) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2684689 | 0.91 | HDAC1 (0.69) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2686463 | 0.90 | HDAC1 (0.70) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2685581 | 0.90 | HDAC1 (0.58) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2684544 | 0.90 | KCNH2 (0.76) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2686607 | 0.90 | HDAC1 (0.66) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL14781030 | 0.88 | HDAC1 (0.65) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL2684972 | 0.88 | HDAC1 (0.65) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL12535805 | 0.87 | HDAC1 (0.66) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991226-B1 | INHIBITORS OF HISTONE DEACETYLASE | MERCK SHARP & DOHME (US) | 2013-03-20 | — | — | EP | claimed |
| US-8168658-B2 | Inhibitors of histone deacetylase | MERCK SHARP & DOHME CORP. (US) | 2012-05-01 | — | — | US | claimed |
| US-20090069250-A1 | Inhibitors of Histone Deacetylase | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | claimed |
| EP-1991226-A2 | INHIBITORS OF HISTONE DEACETYLASE | Merck & Co., Inc. (US) | 2008-11-19 | — | — | EP | claimed |
| WO-2007100657-A2 | INHIBITORS OF HISTONE DEACETYLASE | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | claimed |
| EP-1991226-B1 | INHIBITORS OF HISTONE DEACETYLASE | MERCK SHARP & DOHME (US) | 2013-03-20 | — | — | EP | disclosed |
| EP-1991226-B1 | INHIBITORS OF HISTONE DEACETYLASE | MERCK SHARP & DOHME (US) | 2013-03-20 | — | — | EP | disclosed |
| US-8168658-B2 | Inhibitors of histone deacetylase | MERCK SHARP & DOHME CORP. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168658-B2 | Inhibitors of histone deacetylase | MERCK SHARP & DOHME CORP. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168658-B2 | Inhibitors of histone deacetylase | MERCK SHARP & DOHME CORP. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090069250-A1 | Inhibitors of Histone Deacetylase | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | disclosed |
| US-20090069250-A1 | Inhibitors of Histone Deacetylase | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | disclosed |
| US-20090069250-A1 | Inhibitors of Histone Deacetylase | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | disclosed |
| EP-1991226-A2 | INHIBITORS OF HISTONE DEACETYLASE | Merck & Co., Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007100657-A2 | INHIBITORS OF HISTONE DEACETYLASE | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007100657-A2 | INHIBITORS OF HISTONE DEACETYLASE | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069250-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC6 | HDAC1 1/4885HDAC2 4/4885HDAC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.